BR112021001288A8 - vacinas individualizadas para câncer - Google Patents

vacinas individualizadas para câncer

Info

Publication number
BR112021001288A8
BR112021001288A8 BR112021001288A BR112021001288A BR112021001288A8 BR 112021001288 A8 BR112021001288 A8 BR 112021001288A8 BR 112021001288 A BR112021001288 A BR 112021001288A BR 112021001288 A BR112021001288 A BR 112021001288A BR 112021001288 A8 BR112021001288 A8 BR 112021001288A8
Authority
BR
Brazil
Prior art keywords
patient
tumor
cancer vaccines
individualized cancer
individualized
Prior art date
Application number
BR112021001288A
Other languages
English (en)
Other versions
BR112021001288A2 (pt
Inventor
Sahin Ugur
VORMEHR Mathias
Bukur Thomas
Original Assignee
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Biontech Rna Pharmaceuticals Gmbh
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh, Biontech Rna Pharmaceuticals Gmbh, BioNTech SE filed Critical Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Publication of BR112021001288A2 publication Critical patent/BR112021001288A2/pt
Publication of BR112021001288A8 publication Critical patent/BR112021001288A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001163—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

VACINAS INDIVIDUALIZADAS PARA CÂNCER A presente invenção está no campo da imunoterapia tumoral. Em particular, a presente invenção fornece vacinas individualizadas contra o câncer específicas para o tumor de um paciente com base em uma análise de transcriptoma em uma amostra de tumor do paciente para transcritos de RNA que são excessivamente regulados em uma ou mais células cancerosas do referido paciente. Estas vacinas individualizadas de câncer, quando administradas ao paciente, induzem uma resposta imune contra antígenos associados a tumor expressos em um tumor do paciente pelos transcritos de RNA que são excessivamente regulados positivamente em uma ou mais células cancerosas do referido paciente. Devido à regulação positiva excessiva dos transcritos de RNA, as vacinas individualizadas de câncer são eficazes para a vacinação de um sujeito e para quebrar a autotolerância contra antígenos associados a tumor que são auto-proteínas no referido sujeito.
BR112021001288A 2018-07-24 2019-07-23 vacinas individualizadas para câncer BR112021001288A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2018/070058 2018-07-24
PCT/EP2018/070058 WO2020020444A1 (en) 2018-07-24 2018-07-24 Individualized vaccines for cancer
PCT/EP2019/069813 WO2020020894A1 (en) 2018-07-24 2019-07-23 Individualized vaccines for cancer

Publications (2)

Publication Number Publication Date
BR112021001288A2 BR112021001288A2 (pt) 2021-04-27
BR112021001288A8 true BR112021001288A8 (pt) 2022-10-18

Family

ID=63165326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021001288A BR112021001288A8 (pt) 2018-07-24 2019-07-23 vacinas individualizadas para câncer

Country Status (10)

Country Link
US (1) US20210290746A1 (pt)
EP (1) EP3826668A1 (pt)
JP (1) JP2021532122A (pt)
KR (1) KR20210039376A (pt)
CN (1) CN112533630A (pt)
AU (1) AU2019312509A1 (pt)
BR (1) BR112021001288A8 (pt)
CA (1) CA3106883A1 (pt)
MX (1) MX2021000853A (pt)
WO (2) WO2020020444A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110223188A1 (en) 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
KR20230145545A (ko) * 2013-04-07 2023-10-17 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
JP6513086B2 (ja) * 2013-07-30 2019-05-15 ビオエンテッヒ・アクチェンゲゼルシャフトＢｉｏＮＴｅｃｈ ＡＧ 癌治療法の決定のための腫瘍抗原
CN108430456B (zh) * 2015-10-22 2022-01-18 摩登纳特斯有限公司 癌症疫苗

Also Published As

Publication number Publication date
KR20210039376A (ko) 2021-04-09
JP2021532122A (ja) 2021-11-25
WO2020020444A1 (en) 2020-01-30
BR112021001288A2 (pt) 2021-04-27
CN112533630A (zh) 2021-03-19
US20210290746A1 (en) 2021-09-23
AU2019312509A1 (en) 2021-01-14
MX2021000853A (es) 2021-03-26
EP3826668A1 (en) 2021-06-02
CA3106883A1 (en) 2020-01-30
WO2020020894A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
BR112019018863A8 (pt) Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
CL2021002997A1 (es) Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535)
BR112019010699A2 (pt) receptores de células t e imunoterapia empregando os mesmos
BR112017017293A2 (pt) método para predizer modificações de aminoácidos, para selecionar e/ou classificar modificações de aminoácidos e para fornecer uma vacina e vacina
BR112019010972A2 (pt) receptores de células t e imunoterapia usando os mesmos
BR112017025297A2 (pt) anticorpos anti-gitr para diagnóstico do câncer
BR112017019140A2 (pt) métodos de tratamento de câncer usando células t ativadas
BR112017002080A2 (pt) ?anticorpo monoclonal ou fragmento de ligação, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para preparar o anticorpo monoclonal ou fragmento de ligação, in vivo ou in vitro e para prevenção e/ou tratamento e/ou terapia adjuvante e/ou diagnóstico de um tumor, conjugado, kit, uso de um anticorpo monoclonal ou fragmento de ligação, e, composição farmacêutica?
BR112015020804A2 (pt) dispositivo fototerapeutico, método e uso
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BR112016029713A8 (pt) uso de uma carboximetilcelulose reticulada e uso de um agente gelificante
BR112014009276A8 (pt) uso de inibidores de tirosina quinase de bruton (btk)
BR112012030625A2 (pt) uso de inibidores de tirosina quinase de bruton (btk)
BR112017009151A2 (pt) ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
BR112017001420A2 (pt) método
BR112015030457A2 (pt) Método para regular positivamente a expressão de antígeno
BR112014024487A2 (pt) métodos para aumentar a eficácia da terapia baseada em cd37
BR112021001288A8 (pt) vacinas individualizadas para câncer
BR112019009771A2 (pt) ligação de anticorpos especificamente à cd66c e utilização dos mesmos
WO2015057968A3 (en) Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
BR112018008840A8 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BR112015012507A8 (pt) método in vitro de seleção de um indivíduo diagnosticado ou suspeito de ter câncer e uso de um inibidor de telomerase
BR112016028838A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; BIONTECH SE (DE)